This archive collects solutions-journalism stories and milestones from the United States — covering policy wins, community-led efforts, scientific advances, and social progress happening across the country. Each entry highlights what’s working and why it matters.
PFAS are used in nonstick cookware, stain-resistant fabrics, and firefighting foams, and have been linked with higher cholesterol, lower fertility, developmental delays in children, and a greater risk of cancer.
Companies that sell in Minnesota but don’t offer customers or independent repair shops the materials needed to fix devices within 60 days can be found in violation of state law.
Illinois is poised to become the first U.S. state to outlaw book bans, with House Bill 2789 heading to Governor JB Pritzker’s desk and set to take effect January 1. Rather than criminalizing censorship, the law ties state funding to a clear standard: public libraries and schools must either follow the American Library Association’s Library Bill of Rights or adopt their own written policy against book bans. It’s a creative answer to a real problem — Illinois alone saw 67 attempts to remove books in 2022. As challenges multiply nationwide, often targeting works by LGBTQ+ authors and writers of color, Illinois offers a model other states could borrow: protecting the freedom to read by making censorship costly, not just controversial.
The FDA finalized recommendations for determining donor eligibility by using the same questions for everyone who wants to donate, similar to how the U.K., Canada, and France currently determine risk.
“A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines,” said Dr. Hugh Auchincloss, acting NIAID Director.
The bills protect providers from discipline for providing legally protected reproductive and gender affirming health care services.
Fusion energy just took a big step from lab to grid: Helion Energy has signed the world’s first commercial fusion power purchase agreement, promising Microsoft at least 50 megawatts of electricity from a plant targeted to come online in 2028. That timeline is roughly a decade ahead of most expert projections for commercial fusion. Helion has already built six prototypes and reached the 100-million-degree plasma temperatures considered necessary for self-sustaining reactions, with Constellation handling the grid-side logistics. The engineering road ahead is steep, and nothing is guaranteed. But moving fusion from research aspiration onto a real buyer’s procurement list is a meaningful shift, hinting at a future where zero-carbon baseload power becomes a practical piece of the climate puzzle.
Pfizer’s RSV vaccine ABRYSVO just became the first licensed option for at-risk adults as young as 18, closing a long-standing protection gap for younger people living with chronic conditions. About one in ten U.S. adults aged 18 to 49 has a condition like diabetes, asthma, or heart failure that raises their risk of severe RSV illness — and until now, they had nothing. The vaccine targets RSV’s prefusion F protein, a breakthrough that finally unlocked effective design after decades of frustrating research. With approvals now spanning pregnant individuals, older adults, and at-risk younger adults, ABRYSVO marks a quiet but powerful turning point in a field that struggled for half a century — a reminder that patient science eventually delivers real protection to real people.
“In our first treated case, we were thrilled to see that the aggressive decline usually seen after birth simply did not appear,” said lead author Professor Darren Orbach of Boston Children’s Hospital.
Oregon licensed its first three psilocybin facilitators in April 2023, making it the first U.S. state to formally authorize practitioners to guide adults through psychedelic sessions at regulated service centers. The approvals were part of a much larger pipeline, with more than 300 permit and license applications already submitted and the state’s first psilocybin manufacturer licensed the month prior. Voters had approved this supervised-access model back in 2020, choosing a path that doesn’t require a prescription or diagnosis but does require trained guidance. Real hurdles remain, including local bans in over 100 Oregon cities and open questions about affordability. Still, this is the first legal home in the country for a therapy that researchers increasingly believe could transform how we treat depression, anxiety, and trauma.
